Innate Pharma S.A. (IPHA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Innate Pharma (IPHA) Q1 2026: $825M Milestone Pool Anchors Partnered Pipeline, Non-Dilutive Funding Pathway Advances
May 13, 2026
-
Innate Pharma (IPHA) FY 2025: R&D Spend Down 16% as Pipeline Focus Sharpens Ahead of 2026 Catalysts
March 26, 2026
-
Innate Pharma (IPHA) Q3 2025: $150M Lacutamab Launch Opportunity Anchors Pipeline Focus
November 13, 2025